Salix Pharmaceuticals (SLXP) 101.06 $SLXP
IBD 50: Auto, Other IBD 50 Stocks Forming Bases
at Investor's Business Daily - Thu Apr 17, 5:53PM CDT
Thanks to a longer market contraction, about a dozen IBD 50 stocks are forming bases, making those stocks worth a closer look. The major indexes have sunk longer and deeper than previous declines since the start of 2013. That's given some leading...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
SmarTrend Watching for Potential Rebound in Shares of Salix Pharmaceuticals After 1.38% Loss
Comtex SmarTrend(R) - Mon Apr 14, 4:52PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $96.37 to a high of $101.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $98.16 on volume of 886,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Go Red In Heavy Trade; Gap, JPMorgan, NQ Mobile Dive
at Investor's Business Daily - Fri Apr 11, 9:27AM CDT
Healthy March wholesale price and April consumer sentiment data had no effect on stocks early Friday as indexes opened sliding lower in heavy trade. The Nasdaq and the Dow Jones industrial average were down 0.5% each. The S&P 500 fell 0.4%. Big-money...
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Mallinckrodt to Acquire Questcor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:15PM CDT
Shares of Questcor Pharmaceuticals were up 18.7% after Dublin-based specialty pharmaceutical company Mallinckrodt announced that it has entered into a definitive agreement to acquire the former for $5.6 billion.
Roche Acquires IQuum - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:35PM CDT
In order to strengthen its diagnostics business, Roche announced that it has acquired privately held IQuum, Inc. for $275 million in upfront cash.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Salix Among Stocks Getting Support At 10-Week Line
at Investor's Business Daily - Thu Apr 03, 5:13PM CDT
A number of leading stocks in Your Weekly Review are in a secondary buy range amid the market's renewed uptrend. Stocks in the highly rated Medical-Ethical Drugs industry again led this week's list, which expanded to 109 members after shrinking to...
Salix Pharmaceuticals Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 02, 4:58PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $106.64 to a high of $109.78. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $106.96 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Positive News for Novartis' LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:27PM CDT
Novartis received positive news when the Data Monitoring Committee unanimously recommended the early closure of the phase III study, PARADIGM-HF, on candidate LCZ696.
J&J to Sell Ortho Clinical Diagnostics Biz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 12:50PM CDT
The $4 billion deal is expected to go through in mid-14.
Setback for Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 6:10PM CDT
Novartis suffered a setback when the U.S. Food and Drug Administration (FDA) and Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted against the approval of the candidate RLX030 (serelaxin) for the treatment of acute heart failure.
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
IBD 50: Auto, Other IBD 50 Stocks Forming Bases
at Investor's Business Daily - Thu Apr 17, 5:53PM CDT
Thanks to a longer market contraction, about a dozen IBD 50 stocks are forming bases, making those stocks worth a closer look. The major indexes have sunk longer and deeper than previous declines since the start of 2013. That's given some leading...
Zogenix Shares Soar on Massachusetts Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:30PM CDT
Zogenix announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER on Constitutional grounds.
Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
Flamel Technologies (FLML) in Focus: Stock Slumps 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:54AM CDT
Flamel Technologies (FLML) fell nearly 14% in the last trading session amid high volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
SmarTrend Watching for Potential Rebound in Shares of Salix Pharmaceuticals After 1.38% Loss
Comtex SmarTrend(R) - Mon Apr 14, 4:52PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $96.37 to a high of $101.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $98.16 on volume of 886,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Go Red In Heavy Trade; Gap, JPMorgan, NQ Mobile Dive
at Investor's Business Daily - Fri Apr 11, 9:27AM CDT
Healthy March wholesale price and April consumer sentiment data had no effect on stocks early Friday as indexes opened sliding lower in heavy trade. The Nasdaq and the Dow Jones industrial average were down 0.5% each. The S&P 500 fell 0.4%. Big-money...
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Mallinckrodt to Acquire Questcor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:15PM CDT
Shares of Questcor Pharmaceuticals were up 18.7% after Dublin-based specialty pharmaceutical company Mallinckrodt announced that it has entered into a definitive agreement to acquire the former for $5.6 billion.
Roche Acquires IQuum - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:35PM CDT
In order to strengthen its diagnostics business, Roche announced that it has acquired privately held IQuum, Inc. for $275 million in upfront cash.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Salix Among Stocks Getting Support At 10-Week Line
at Investor's Business Daily - Thu Apr 03, 5:13PM CDT
A number of leading stocks in Your Weekly Review are in a secondary buy range amid the market's renewed uptrend. Stocks in the highly rated Medical-Ethical Drugs industry again led this week's list, which expanded to 109 members after shrinking to...
Salix Pharmaceuticals Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 02, 4:58PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $106.64 to a high of $109.78. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $106.96 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Positive News for Novartis' LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:27PM CDT
Novartis received positive news when the Data Monitoring Committee unanimously recommended the early closure of the phase III study, PARADIGM-HF, on candidate LCZ696.
J&J to Sell Ortho Clinical Diagnostics Biz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 12:50PM CDT
The $4 billion deal is expected to go through in mid-14.
Setback for Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 6:10PM CDT
Novartis suffered a setback when the U.S. Food and Drug Administration (FDA) and Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted against the approval of the candidate RLX030 (serelaxin) for the treatment of acute heart failure.
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
